Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Notes Payables (2016 - 2017)

Editas Medicine (EDIT) has disclosed Notes Payables for 2 consecutive years, with $7.5 million as the latest value for Q4 2017.

  • Quarterly Notes Payables fell 25.0% to $7.5 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2017, down 25.0% year-over-year, with the annual reading at $7.5 million for FY2017, 25.0% down from the prior year.
  • Notes Payables for Q4 2017 was $7.5 million at Editas Medicine, down from $15.0 million in the prior quarter.
  • The five-year high for Notes Payables was $15.0 million in Q1 2017, with the low at $7.5 million in Q4 2017.